Eprex 3000 IU (IV/SC Injection)

3000 IU pre-filled syringe: ৳ 1,950.00 (1 x 6: ৳ 11,700.00)

Medicine Details

Category	Details
Generic	Erythropoietin alfa
Company	Cilag ag switzerland
Also available as	Eprex 2000 iu injection Eprex 4000 iu injection Eprex 10000 iu injection

Therapeutic Class

Drugs for Haemolytic Hypoplastic & Renal Anemia

Indications

Treatment of anemia in Chronic Kidney Disease (CKD) patients on dialysis and not on dialysis
Treatment of anemia due to Zidovudine in HIV-infected patients
Treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy
Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery
Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 gm and gestational age of less than 34 weeks

Description

Recombinant human erythropoietin (EPO) expressed in Chinese hamster ovary cells with a 165 amino acid sequence identical to that of human urinary EPO.

Dosage

Evaluate iron status before and during treatment
Monitor hemoglobin levels at least weekly until stable, then at least monthly
Do not increase the dose more frequently than once every 4 weeks
For patients on dialysis, initiate treatment when hemoglobin level is less than 10 g/dL
For patients not on dialysis, consider initiating treatment only when hemoglobin level is less than 10 g/dL
Starting dose for Zidovudine-treated HIV-infected Patients is 100 units/kg 3 times per week
Administer Erythropoietin alfa subcutaneously at a dose of 3x250 IU/kg b.w. per week for the prevention of anemia of prematurity

Administration

Do not shake or freeze the product
Protect syringe from light
Inspect visually for particulate matter and discoloration before administration
Discard unused portions of Erythropoietin alfa

Interaction

Effect of Eprex may be potentiated by the simultaneous therapeutic administration of a haematinic agent such as ferrous sulphate when a deficiency state exists

Contraindications

Uncontrolled hypertension
Serious allergic reactions to Erythropoietin alfa
Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin

Side Effects

Adverse reactions in 5% of Eprex treated patients in clinical studies include hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, upper respiratory tract infection
Adverse reactions in Zidovudine-treated HIV-infected Patients include pyrexia, cough, rash, and injection site irritation
Adverse reactions in Cancer Patients on Chemotherapy include nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, headache, depression, dysphagia, hypokalemia, and thrombosis
Adverse reactions in Surgery Patients include nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension
Premature infants may experience a fall in serum ferritin values

Pregnancy & Lactation

Use in pregnancy only if potential benefit outweighs potential risk to the fetus
Not recommended in pregnant or lactating surgical patients participating in an autologous blood predonation programme
Use with caution in nursing women

Overdose Effects

Eprex overdosage can cause hemoglobin levels above the desired level, which should be managed with discontinuation or reduction of Eprex dosage and/or with phlebotomy

Storage Conditions

Store at 2°C to 8°C, do not freeze or shake, store in the original package to protect from light